Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

Inclusion Criteria:

- Must be 18 to 45 years of age, inclusive.

- Absence of diseases, such as heart failure, significant kidney impairment or a history
of restricted blood flow to the heart, that could affect the study outcomes.

- Having a body mass index (BMI) within normal standard limits (18.5~24.9, inclusive).

- Willing and able to give informed consent to participate in the clinical study and
comply with all study procedures, restrictions and attend all visits.

Exclusion Criteria:

- History of bleeding tendency.

- Use of anticoagulant agent(s) within 1 month prior to screening.

- Use of tobacco or nicotine products within 6 months of screening.

- Intake of over the counter or prescription drugs (other than hormonal contraceptives)
within 2 weeks prior to randomization.

- On any investigational drug(s) or therapeutic device(s) within 30 days preceding
screening; or anticipating use of any of these therapies during the course of the
study (other than the study products).

- History of substance abuse, such as alcohol, IV drugs, and inhaled drugs, within 1
year prior to screening.

- Known history of having Acquired Immunodeficiency Syndrome (AIDS) or positive
pre-study result of infection with Human Immunodeficiency Virus (HIV); history or
positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result
within 3 months of screening.

- Pregnant or breast feeding.

- Women of child-bearing potential not using an effective birth control method. Women of
child-bearing potential are defined as women physiologically capable of becoming
pregnant, UNLESS they meet the following criteria:

1. Post-menopausal: 12 months of natural (spontaneous) amenorrhea or less than 12
months of spontaneous amenorrhea with serum Follicle Stimulating Hormone (FSH)
levels > 40IU/L, OR;

2. 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy, OR;

3. Using one or more of the following acceptable methods of contraception: surgical
sterilization (e.g. bilateral tubal ligation), hormonal contraception (e.g.
implantable, injectable, vaginal patch, and oral), and double-barrier methods.
Reliable contraception should be maintained throughout the study and for 7 days
after study discontinuation.

- Known or suspected hypersensitivity to any ingredient of study drug(s).

- Donated blood or lost more than 150 mL of blood within 3 months prior to randomization
or plans to donate blood or plasma within 4 weeks after completion of the study.